NCT03603405View on ClinicalTrials.gov

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
GlioblastomaAnaplastic Astrocytoma
Interventions
DRUG

ADV/HSV-tk (gene therapy)

The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy

Trial Locations (1)

77030

RECRUITING

Houston Methodist Neurological Institute, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER